Citadel Advisors
SRRA

Citadel Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Citadel Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,000
Closed -$605K – 14296
2022
Q2 		$605K Sell
11,000
-9,000
-45% -$472K ﹤0.01% 8210
2022
Q1 		$641K Buy
+20,000
New +$574K ﹤0.01% 8794

Other funds holding SRRA

HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Citadel Advisors's SRRA Position: Q3 2022 in Review

Citadel Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 6,406 shares — an estimated $352K sold.

Citadel Advisors first reported a position in SRRA in Q3 2015 and held it in 12 quarters. The position peaked at $15M in Q1 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • Citadel Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 6,406 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $352K.
  • Citadel Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 12 quarters.
  • Citadel Advisors's Sierra Oncology, Inc. Common Stock position peaked at $15M in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.